Aarti Drugs Ltd

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Drugs Ltd commenced trading today with a pronounced gap down, opening 6.63% lower at Rs 342.65, reflecting heightened market apprehensions following recent developments. The stock’s weak start underscores ongoing pressures within the Pharmaceuticals & Biotechnology sector, as it continues to underperform both its sector peers and the broader market indices.

Aarti Drugs Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Feb 2026, reflecting deteriorating technical indicators and disappointing financial performance. The company’s Mojo Score has slipped to 28.0, signalling heightened caution for investors amid a bearish technical outlook, weakening profitability, and subdued valuation metrics despite some operational strengths.

Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish to a more pronounced bearish trend. Despite a marginal day decline of 0.23%, the stock’s technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, signal increasing downside pressure. This comprehensive analysis explores the evolving technical landscape of Aarti Drugs Ltd, contextualising its performance against broader market benchmarks and sector dynamics.

Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 February 2026, reflecting a nuanced shift in its technical outlook and valuation metrics despite ongoing financial challenges. The pharmaceutical company’s Mojo Score has improved to 34.0, signalling a cautious but more optimistic stance amid mixed performance across quality, valuation, financial trends, and technical indicators.

Aarti Drugs Ltd has experienced a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a modest day gain of 0.22%, the stock’s broader technical signals and relative performance against the Sensex suggest cautious investor sentiment amid ongoing sector challenges.

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Drugs Ltd has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Strong Sell. This nuanced change in price-to-earnings and price-to-book ratios, when analysed against sector peers and historical benchmarks, presents a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector in early 2026.

Aarti Drugs Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial performance for the quarter ended December 2025. The company’s recent quarterly results reveal a shift from positive to negative financial trends, with significant contraction in profitability and operating margins, raising concerns among investors and analysts alike.

Aarti Drugs Ltd., a prominent manufacturer of active pharmaceutical ingredients (APIs), pharma intermediates, and speciality chemicals, reported consolidated net profit of ₹40.54 crores for Q3 FY26, declining 10.47% quarter-on-quarter from ₹45.28 crores in Q2 FY26, though registering a 9.42% year-on-year improvement from ₹37.05 crores in Q3 FY25. The ₹3,331.81 crore market capitalisation company faced significant profitability headwinds during the quarter despite maintaining revenue momentum, with shares plunging 6.80% following the results announcement.

Aarti Drugs Ltd commenced trading today with a pronounced gap down, opening at Rs 355, marking a 9.37% decline from its previous close. This sharp drop reflects heightened market concerns following recent developments, resulting in notable volatility and a break in the stock’s prior upward momentum.

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.